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Summary This report reviews 48 patients who from 1979 to 1994 were treated at the Norwegian Radium Hospital for newly diagnosed non-
cerebral extragonadal malignant germ cell tumour (EGGCT). Based on histology and/or serum tumour markers, 12 patients had a seminoma
and 36 a non-seminoma. At diagnosis, 33 and 15 patients were classified as having abdominal and mediastinal EGGCT respectively. At the
time of diagnosis 13 patients, all with non-seminomatous tumours, had metastases to bone, liver or brain. One patient with abdominal
seminoma was cured by radiotherapy alone, whereas cisplatin-based chemotherapy (with or without surgery) was planned in the 47
remaining patients. Twenty-seven out of 42 patients receiving four or more chemotherapy cycles were rendered tumour free by induction
chemotherapy, including 5 of the 13 patients with extralymphatic non-pulmonal disease. An additional tumour-free patient died of septicaemia
after only two cycles ofchemotherapy. Late relapses (after > 2 years) were observed in three patients, and a testicular primary was diagnosed
during follow-up in three cases. Seven patients died of treatment-related complications, five ofthese because of neutropenic septicaemia. The
median age of these patients was 52 years compared with 35 years in the remaining 41 patients (P< 0.05). The 5-year overall survival for all
48 patients was 60% (95% Cl 46-74%) [cancer-specific 5-year survival 71% (95% Cl 50-92%)]. EGGCT is a potentially curable disease, even
in patients with very advanced disease. Special attention should, however, be devoted to patients above the age of 40 years because of an
increased risk of treatment-related side-effects. Late relapses and the subsequent development of testicular tumours indicate the need for
long-term follow-up.
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Germ cell malignancy, most often presenting as testicular cancer,
is the most common malignancy in young adult men aged 15-35
years, and the incidence of testicular cancer is increasing.
Extragonadal germ cell tumour (EGGCT) is a rare subgroup of
germ cell malignancy mostly affecting men, although it may also
be diagnosed in women. EGGCTs are most frequently detected in
mediastinum and retroperitoneal lymph nodes, but have also been
described in the central nervous system (Johnson et al, 1973), liver
(Hart, 1975) and prostate gland (Dvoracek, 1949). The pathogen-
esis ofEGGCT remains unknown. It has been suggested that there
is a pathogenetic difference between mediastinal and retro-
peritoneal manifestation of EGGCT (Nichols et al, 1987). More
recent observations, however, indicate the mediastinal EGGCT
and primary testicular cancers may be cytogenetically similar
(Chaganti et al, 1994) suggesting the same origin for all germ cell
tumours. Daugaard et al (1992) have reported that biopsies from
testis in patients with retroperitoneal EGGCT showed testicular
carcinoma in situ (CiS) in 42% of the patients (Daugaard et al,
1992). According to those authors, testicular CiS was not found in
any ofthe eight patients with mediastinal EGGCT. Based on these
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findings, the hypothesis was put forward that some cases of
retroperitoneal EGGCT may be due to a primary testicular cancer
with metastases to the retroperitoneal lymph nodes and subsequent
necrosis ofthe primary tumour, thus finally presenting as EGGCT.
Testicular cancer has become a model of a curable metastatic
solid malignant tumour. In most reports, the survival rates of
patients with EGGCT are, however, inferior compared with those
ofpatients with advanced testicular cancer, although the treatment
regimens are often the same for both conditions.
In this report, we describe the findings at the time of diagnosis
and the outcome of all 48 patients diagnosed and treated for
EGGCT at the Norwegian Radium Hospital (NRH) during the
period 1979-95, i.e. from the time when cisplatin-based
chemotherapy became available in Norway.
PATIENTS AND METHODS
Patients
This series comprises all 48 patients treated for EGGCT at the
Norwegian Radium Hospital (NRH) between 1979 and 1994.
Thirty-six patients treated within 1991 had previously been
entered into the series of the Intemational Germ Cell Cancer
Collaborative Group (IGCCCG) (International Germ Cell Cancer
Collaborative Group, 1997). Forty-three cases were classified as
extragonadal germ cell tumours by malignant germ cell histology
of a mid-line tumour. In five patients with mid-line tumours,
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Table 1 Definition of the Germ Cell Consensus Classification
Prognosis
Good Intermediate Poor
Non-Seminoma with all of: with all of: with ANY of:
* Testis/retroperitoneal primary * Testis/retroperitoneal primary * Mediastinal primary
* No non-pulmonary visceral metastases * No non-pulmonary visceral metastases * Non-pulmonary visceral metastases
* AFP < 1000 ng ml-' and * AFP > 1000 and < 10 000 IUll or * AFP > 10 000 ng 1-' or
HCG < 1000 ng ml-' and HCG .5000 IU I-' and < 50 000 IU -11 or HCG > 50 000 IU 1-1(100 000 ng ml-' or
LDH < 1.5 x upper limit of normal LDH . 1.5 x N and < N and 10 x N LDH > 10 x upper limit of normal
56% of non-seminomas 28% of non-seminomas 16% of non-seminomas
5-year PFS 89% 5-year PFS 75% 5-year PFS 41%
5-year survival 92% 5-year survival 80% 5-year survival 48%
Seminoma with all of: with all of: with ANY of:
* Any primary site and * Any primary site and No patients classified as poor prognosis
* No non-pulmonary visceral metastases * No non-pulmonary visceral metastases
* and Normal AFP * and Normal AFP
Any HCG Any HCG
Any LDH Any LDH
90% of seminomas 10% of seminomas
5-year PFS 82% 5-year PFS 68%
5-year survival 86% 5-year survival 73%
PFS, progression-free survival; N, normal.
histology revealed necrosis only, and the diagnosis ofEGGCT was
made by elevated serum levels of human choriogonadotropin
(HCG) or alfafetoprotein (AFP). In all cases, the testicles or
ovaries were considered to be tumour free by clinical orultrasono-
graphic examination. Testicular biopsies before treatment were
performed in the 36 patients treated after 1985 withoutevidence of
invasive testicular malignancy. (The results will be further
discussed in a separate paper.) All patients had computerized
tomography (CT) of the chest and the abdomen before start of
treatment. Based on the largest tumour manifestation, the primary
site of the malignancy was categorized as either abdominal or
mediastinal. Ifpossible, histology was described according to the
World Health Organization (WHO) classification for malignant
germ cell tumours. However, in nine patients with proven germ
cell malignancy, the subtype could not be determined. In these
nine cases of proven germ cell malignancy and in the five above-
mentioned patients with pure necrosis in the biopsy, elevated
serum AFP (any level above the normal range) or elevated serum
HCG > 30 000 U 1- (one case) was considered to prove the
presence of a non-seminoma. Following these definitions, 3 ofthe
above 14 cases were classified as seminomas and 11 as non-semi-
nomas. The upper normal reference values were 10 U 1-1 forHCG;
20 gg 1-1 for AFP and 450 U 1-1 for LDH.
Based on histology, localization ofthe metastases and the initial
level of serum AFP, HCG and LDH, all 48 patients were catego-
rized into prognostic groups according to the classification of the
IGCCCG (Table 1), with the modification that the two women
were included.
Treatment
One patient with abdominal seminoma without mediastinal
involvement and normal serum HCG and AFP values received
abdominal and mediastinal radiotherapy (40 Gy) as his only treat-
ment. Depending on the institution's policy at the time of diag-
nosis, the other 47 patients received cisplatin-based chemotherapy
as described previously for testicular cancer (Fossa et al, 1988;
Lewis et al, 1991). The type ofprimary treatment and the number
of cycles of chemotherapy given are summarized in Table 2.
Because of the advanced stage in many of these patients with
EGGCT, rather intensive chemotherapy schedules were frequently
selected. In general, the application of at least four cycles were
planned in each patient. Ifafter four or more chemotherapy cycles
the serum tumour markers were normal or had reached a plateau,
but residual masses were detectable in the absence ofnew lesions,
post-chemotherapy resection of these masses was principally
scheduled in patients with non-seminoma, but not in those with
seminoma.
Response
At the end of the initial treatment containing at least four
chemotherapy cycles, three response categories were identified.
Complete response
Complete response required the normalization of clinical, radio-
logical and serological findings by chemotherapy alone or after
post-chemotherapy resection ofresidual masses. Histology ofsuch
masses could either be fibrosis/necrosis, mature or viable malig-
nant tumour. (There was no patient with residual viable malignant
tumour with only a biopsy or an incomplete resection.)
Inevaluable forresponse
A patient was inevaluable for response when there was the
persistence of unbiopsied and unresectable tumour masses in
the presence ofnormal tumour markers.
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CVB, cisplatin (100 mg m-2 per cycle), vinblastine, bleomycin; BEP20, as
CVB, but vinblastine substituted by etoposide; high-dose cisplatin, as CVB or
BEP20, but cisplatin 180-200 mg m-2 per cycle; BOPNIP, bleomycin,
oncovin, cisplatin/etoposide, ifosphamide, cisplatin; CEB, as BEP20, but
cisplatin substituted by carboplatin. aRadiotherapy only. bHigh.dose cisplatin-
based chemotherapy planned but not given because of treatment-related
respiratory failure starting during the prehydration phase.
Progression
Progression was defined as rising serum tumour markers or the
development ofnew tumour manifestations. (Plateau development
of serum tumour markers was not observed in any ofthe patients.)
Patients receiving less than four of the planned cycles of
chemotherapy because of treatment toxicity were considered to be
non-assessable for response.
Survival
All patients were followed-up to death or to 1 January 1997, the
median observation time for surviving patients being 96 months
(range 29-192 months). Overall survival and cancer-specific
survival were assessed, the latterevaluating death due to the malig-
nant disease only (with the exclusion ofpatients with a toxic death
due to post-operative orchemotherapy-related complications).
Statistics
Standard statistical tests were used (median, range, Wilcoxon
rank-sum test, chi-square test). Survival was assessed using the
Kaplan-Meier procedure with the log-rank test for evaluation of
differences between survival curves. All survival rates are given
with their 95% confidence interval (95% CI). A P-value of < 0.05
was regarded as being statistically significant.
RESULTS
Initial work-up
The median age of all patients was 36 years (range 19-75 years)
(Table 3). The patients with seminoma had a median age of 52
years (range 24-70 years) compared with the median age of 32
years for patients with non-seminoma (P < 0.02). Thirty-three
patients had an abdominal extragonadal tumour, in 15 patients
combined with a primary mediastinal tumour. In 15 patients, the
mediastinal was presumed (Table 2), nine ofthese also presenting
with abdominal mass. TWo patients were women, both with medi-
astinal primaries. All 13 patients with extrapulmonal haematoge-
neous metastases (liver, seven; bone, four; brain, one; brain + liver,
1) had a non-seminomatous tumour. Using the IGCCCG system
(with the above modifications) for germ cell tumours, 12 patients
belonged to the good-prognosis group, 11 patients to the interme-
diate-prognosis group and 25 patients to the poor-prognosis group.
Post-chemotherapy surgery
A total of33 patients hadpost-chemotherapy surgery, scheduled as
a part of their primary treatment. Retroperitoneal surgery was
performed in 23 patients and thoracotomy in eight. One patient
underwent post-chemotherapy axillary gland dissection and in
another a residual mass was resected from the left supraclavicular
fossa. Necrosis or fibrosis was found in 18 patients, mature
teratomain six and viable malignanttumourtissue in ninepatients;
in one of these nine patients the resected initially non-seminoma-
tous primary mediastinal tumour contained viable malignant germ
cell tissue combined with rhabdomyosarcoma. The patient died
during the post-operative course. At autopsy, malignant histocy-
tosis of the lymphatic tissue, of the bone marrow and in the liver
was demonstrated.
Response
One patient with abdominal seminoma was rendered tumour free
by radiotherapy alone. Twenty-seven of42 patients receiving four
or more chemotherapy cycles showed a complete response.
Among these complete responders, there were five (out of 13)
patients, who initially presented with metastases to the brain, liver
or bones. Two further patients were recorded to be tumour free
after post-chemotherapy surgical excision of viable cancer tissue.
Four patients were inevaluable for response, whereas progression
was recorded in nine patients. The remaining five patients were
non-assessable for response as they received three or less
chemotherapy cycles. One of them was, however, tumour free at
autopsy, which was performed after he had died because of
septicaemia after his second cycle.
Relapse and salvage treatment
Four of the 30 completely responding patients relapsed as did all
four patients who were inevaluable for response at the end of
primary chemotherapy. The former four cases included both
patients in whom viable malignant tumour tissue was resected.
They could not be salvaged by available chemotherapy (Hollender
et al, 1997). Two other patients relapsing after initial complete
response became tumour free, but both developed a second relapse
7 and 9 years after this first salvage treatment. Two of the four
patients inevaluable for response progressed shortly after their
initial chemotherapy and were not salvaged. The third patient with
the mediastinal seminoma responded completely to repeated
chemotherapy and radiotherapy, but developed a second incurable
relapse 3 years thereafter. In the fourth patient with inevaluable
response, the residual mediastinal tumour increased in size 3 years
after chemotherapy discontinuation. The subsequent resection of
the tumour revealed a growing mature teratoma. He has remained
without evidence ofdisease thereafter.
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Table 3 Patient demographics at diagnosis
Abdominal Mediastinal
Number of patients 33 15
Median age (range) (years) 35 (23-75) 35 (18-52)
Primary histology
Pure seminomaa 8 1
Embryonal carcinomaa 6 1
Choriocarcinomaa 5 6
Yolk saca 3 4
Necrosis/no histology 3 2







Abdominal 10c (23-250)d (33)e 40 (23-78) (7)
Mediastinal 45 (35-100) (8) 127 (16-210) (15)
Pulmonary 20 (5-70) (7) 40 (30-220) (5)






Liver + brain 1
Serum tumour-markers
HCG (IU I-') 150 (5-880000) 74 (5-453 000)
AFP (gg I-') 5 (5-100000) 1100 (5-100000)
LDH (U I-') 1302 (307-8525) 892 (315-2202)
No. of patients with elevated HCG
(> 10 UI-1)f 23 (18/5) 9 (8/1)
No. of patients with elevated AFP
(> 20gg/l-1)> 7 8
No. of patients with elevated
LDH (21.5 x n)' 26 (18/8) 9 (8/1)
aDominant component in the pretreatment biopsy. bBased on primary
histology or serum tumour markers. cMedian. dRange. eNo. of patients. Total
(non-seminoma/seminoma).
Survival
At the end of the observation time, 27 patients were alive, and 21
patients have died. Twenty-six of the surviving patients were
without evidence of disease at the last observation (abdominal
primary, 19 outof33; mediastinal primary, 7 outof 15). One patient
is alive with rising serumAFP, 13 years afterthe initial diagnosis of
an abdominal EGGCT with cerebral metastases. Fourteen patients
have died oftheir malignancy, whereas seven patients died because
of treatment-related complications (vide infra). The 5-year overall
survival rate forall 48 patients is 60% (95% CI 50-100%) and 71%
(95% CI 50-92%) as regards cancer-specific survival (Figure 1).
One additional death due to EGGCT occurred 12 years after the
primary diagnosis of a mediastinal mature teratoma. The outcome
forthe 12patients with seminomarevealed a5-year overall survival
rate of 75% (95% CI 50-100%) (including the successfully irradi-
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Figure 1 Five-year overall (-) and cancer-specific (A) survival of all 48
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Figure 2 Five-year cancer-specific survival in 48 patients with extragonadal
germ cell tumour according to the IGCCCG classification. *, Good/
intermediate prognosis; O, poor prognosis
rate for the 36 patients with non-seminomatous histology. The 5-
year overall survival for the 33 patients with abdominal tumours
was 63% (95% CI 46-80%), whereas it was 53% (95% CI
28-78%) for the 15 patients with mediastinal primaries. Using the
IGCCCG classification system with the above modifications, the
overall 5-year survival for the combined good-intermediate group
was 69% (95% CI 50-88%) compared with 52% (95% CI 32-72%)
for the poor-risk patients (Figure 2), the respective figures for
5-year cancer-specific survival being 80% (95% CI 62-98%) and
62% (95% CI 41-63%) (Figure 3).
Toxic deaths
Atotalofsevenpatients diedbecause oftreatment-related complica-
tions (Table4). Patient no. 1 who, at the time ofdiagnosis, had more
than 50 lung metastases and a large mediastinal tumour, died from
pulmonary insufficiency during the prehydration phase of the first
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Figure 3 Five-year overall survival in 48 patients with extragonadal germ
cell tumour according to the IGCCCG classification. *, Good/intermediate
prognosis (23 patients); O, poor prognosis (25 patients)
scheduled chemotherapy cycle before any cytostatic drugs were
given. Three patients (nos 4, 6 and 7) died after the first cycle and
one (no. 2) after two cycles because of chemotherapy-induced
neutropenic septicaemia. These patients received chemotherapy
before granulocyte colony-stimulating factor (G-CSF) was avail-
able. The remaining two patients received fourandfivecycles. They
underwent post-chemotherapy surgery for residual mediastinal
masses, but died ofpost-operative complications. Two of the seven
patients who died oftreatment-related complications (patients no. 2
and6) were tumourfreebased on thehistological examination ofthe
operation specimen or on the results ofautopsy. The median age of
the seven patients with fatal treatment-related complications was
52 years compared with 33 years for the remaining 41 patients
(P< 0.05). Only one of the seven patients who died of treatment-
related causes was below the age of40 years. The ages of the four
patients who diedofsepticaemia afterreceiving only 1 or2 cycles of
chemotherapy were 47, 51, 70 and 76 years.
Subsequent testicular cancer
Three patients developed an invasive testicular cancer 3, 10 or 11
years after the diagnosis of EGGCT. In the two patients with an
abdominal non-seminomatous EGGCT, the subsequent testicular
histology revealed a pure seminoma in one case and non-semi-
noma in the other. The third patient with an initial mediastinal pure
seminoma (without abdominal manifestations) developed a stage
II non-seminoma 3 years after the diagnosis ofEGGCT and simul-
taneous testicular carcinoma in situ ofhis left testicle. (His malde-
scent right testicle had been removed during puberty.)
DISCUSSION
In this report, we describe the clinical course of 48 cases with
extragonadal extracerebral germ cell tumours diagnosed over a
period of 15 years in a geographically defined area ('Health region
II') of about 1.5 million people. Our study comprises all patients
seen at the NRH during this period, including a patient who died
after only having received prehydration before any chemotherapy
was administered. All patients with this diagnosis in our Health
region were referred to the NRH. Our experience therefore indi-
cates an incidence of extragonadal germ cell tumour of 0.5 per
100 000 per year. This represents about 2% of the number of
testicular cancer patients in the same population during the same
time period.
It has been suggested that mediastinal and retroperitoneal
EGGCTs have different pathogenesis and tumour biology, the
former sometimes combined with haematological malignancies at
Table 4 Patients with toxic deaths
Patient Age Primary Histology HCG AFP Treatment Complications Time to death
no. (years) site of (IU I)-' (hg l-1) after start
metastasis of treatment
1 41 Mediastinal Non-seminoma 181 000 5 Oa Acute respiratory failure 3 days
Lung/liver
2 75 Abdominal Seminoma 12000 5 Two cycles Neutropenic septicaemia 1 month
BEP20
3 18 Mediastinal Non-seminoma 66 2.960 Five cycles Post-operative complications 5 months
BOPNIP
Thoracotomy
4 47 Abdominal Non-seminoma 782 000 5 One cycle Neutropenic septicaemia 20 days
Liver BEP20
5 53 Mediastinal Non-seminoma 31 270 5 Four cycles Post-operative complications 4 months
BOPNIP
Thoracotomy
6 51 Abdominal Seminoma 17 5 One cycle Neutropenic septicaemia 1 month
High-dose cisplatin
7 70 Abdominal Seminoma 40 5 One cycle Neutropenic septicaemia 11 days
CVB
aPlanned high-dose cisplatin-based chemotherapy.
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the time ofdiagnosis or after treatment (Nichols et al, 1985, 1987).
This is in agreement with the observation ofhistocytosis in one of
our patients with malignant mediastinal EGGCT. Recently, it has
also been suggested that some retroperitoneal EGGCTs may repre-
sent metastases from a testicular cancer with subsequent sponta-
neous necrosis of the primary tumour (Daugaard et al, 1992). On
the other hand, Chaganti et al (1994) suggested the same origin of
all germ cell tumours based on cytogenetic studies. In our series,
only about 40-50% of the tumours were confined to either medi-
astinum or to the abdomen, making it at times difficult to clearly
determine an abdominal or mediastinal origin.
At the time ofpresentation, most of the patients have advanced
disease, 29% of our patients presenting with extrapulmonary
haematogeneous spread. Many clinical investigators consider
patients with EGGCT to have apoorprognosis without taking into
account the extent of disease. Although it is true that the survival
of these patients is below that of patients with testicular cancer
(Feun et al, 1980; Gonzalez-Vela et al, 1992), only about half of
our patients with EGGCT belonged to the IGCCCG poor-prog-
nosis group. As in the IGCCCG series, patients with a seminoma-
tous EGGCT generally had a more favourable diagnosis than those
with a non-seminomatous tumour.
Thepretreatmentestablishmentofaspecific histological diagnosis
may sometimes be difficult in patients with EGGCT, particularly as
treatment often has to be started in an emergency situation. The
determination of germ cell tumour serum markers (HCG, AFP) is
critical for the diagnosis of EGGCT and subtyping. Often, high
serum markers have to be taken as proofofgerm cell malignancy in
the case ofmid-line tumours in youngerpatients. Using these guide-
lines, the ratio ofseminoma to non-seminoma in our patient popula-
tion was 1:3. Others have reported ratios from 1:1.1 to 1:2.5
(GutierrezDelgadoetal, 1993; Goss etal, 1994; Gerl etal, 1996). All
patients with haematogeneous metastases to extrapulmonary organs
had a non-seminoma, indicating the tendency of these tumours to
metastasize to brain, bone orlivercompared with seminoma.
Our results indicate that even patients with far-advanced extra-
gonadal germ cell tumours can be cured by intensive chemo-
therapy with a 5-year overall survival of 60% and a 5-year
cancer-specific survival of 71%. Of the 28 patients with a
complete response to chemotherapy (27) or radiotherapy (one),
27 are alive. These figures are higher than reported by two
other groups (Gonzalez-Vela et al, 1992; Gutierrez Delgado et al,
1993), but similar to results published by Goss et al (1994). In
contrast to these results, none of 11 patients who had progressed at
the end of primary chemotherapy treatment or had viable tumour
cells in post-chemotherapy biopsies was durably salvaged by
second-line treatment. This low cure rate is similar to that reported
by others (Saxman et al, 1994; Gerl et al, 1996) for similar
EGGCT patients.
The median age of our patients with extragonadal germ cell
tumours was 35 years, which is about 10 years older than reported
in the literature (Gonzalez-Vela et al, 1992; Goss et al, 1994). The
high median age of our patients may explain our relatively high
rate ofdeaths because ofcomplications. In particular, our observa-
tions suggest that the risk of fatal neutropenic septicaemia
increases with higher age. In 'older' patients, the bone marrow
may be less functional than in younger patients with advanced
germ cell malignancies. Special attention and care should there-
fore be devoted to these 'older' patients with EGGCT during
chemotherapy. G-CSF should probably be administered at an early
phase of their treatment to avoid complications as a result of
reduced bone marrow function.
For the clinician, it is important to be aware ofthe possibility of
late recurrences (2 2 years after treatment discontinuation) as seen
in 3 of32 patients at risk. Furthermore, patients with EGGCT may
develop testicular tumours many years after their initial diagnosis,
as also pointed out by Daugaard et al (1987) and Gerl et al (1996).
These clinical observations suggest multicentricity of the germ
cell malignancy, at least in some patients.
In summary, patients with extragonadal germ cell tumours often
present with far advanced tumour manifestations. However, only
about 50% of the consecutive patients seen at a major oncology
centre belonged to the poor-prognosis group as defined by the
IGCCCG. EGGCT is sensitive to cisplatin-based chemotherapy
and patients should be treated with intention to cure, even when
presenting with metastases to bone, liver or brain. An overall 5-
year survival of 60% was obtained with a cancer-specific 5-year
survival of71%. Recurrences and new manifestations ofgerm cell
malignancy may develop after several years. Intensive cisplatin-
based chemotherapy ofthese patients with widespread metastases
carries a considerable risk of severe treatment-related complica-
tions, in particular, ofneutropenic septicaemia in patients over the
age of40 years.
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